Carmat Suspends Heart Implants Due to Quality Problem

Paris, France-based Carmat has temporarily suspended implantation of its Aeson artificial hearts because of a quality problem.

The company said it is investigating the problem with the artificial heart, which offers a therapeutic alternative for people suffering from end-stage biventricular heart failure, but did not offer more details of the quality snag in its suspension notice.

“Quality issues are common events in the lifecycle of medical devices, especially during the production ramp-up phase,” said Stéphane Piat, the company’s CEO.